Scarica l'app Stockscreener
99.87
0.42%
0.42
Pre-mercato:
99.85
-0.02
-0.02%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Merck Co Inc Borsa (MRK) Ultime notizie
2 Reasons to Sell Merck Stock and 1 Reason to Buy - The Motley Fool
Merck & Co., Inc. (NYSE:MRK) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Merck & Co. Inc. stock rises Tuesday, still underperforms market - MarketWatch
Merck strikes a $2B GLP-1 deal with Hansoh - BioWorld Online
Wildlife Health Market May See a Big Move | Merck, C.H. Boehringer Sohn - openPR
Merck to discontinue drug for bacterial infection - Reuters
Merck: A Low-Hanging Fruit To Pick (NYSE:MRK) - Seeking Alpha
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and MoreEli Lilly (NYSE:LLY) - Benzinga
Merck - Contract Pharma
Merck-AstraZeneca breast cancer drug reduces risk of death by 28% in patients diagnosed early, clinical trial shows - AOL
Merck & Co., Inc. (NYSE:MRK) Trading Down 0.8%Time to Sell? - MarketBeat
Merck & Co Inc (MRK) Stock Price, Trades & News - GuruFocus.com
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know - MSN
Merck: LM-299 antibody agreement finalized - Marketscreener.com
BMO cuts rating on Merck and Biogen, on lack of near term catalyst - Investing.com
Investing in Merck (NYSE:MRK) three years ago would have delivered you a 43% gain - Yahoo Finance
Merck & Co., Inc. (NYSE:MRK) Rating Lowered to "Market Perform" at BMO Capital Markets - MarketBeat
Merck’s doravirine/islatravir combo yields positive results in Phase 3 HIV-1 trials - World Pharmaceutical Frontiers
Merck secures global rights to novel cancer therapy - Investing.com
Is Merck & Co. (MRK) a Cheap NYSE Stock to Invest in Now? - Insider Monkey
Merck & Co buoyed by Phase III results with HIV tablet - The Pharma Letter
Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet - Simply Wall St
Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody - Business Wire
Analyst recommendations: Fedex, Merck, Nike, Coinbase, Tesla... - Marketscreener.com
Merck stock downgraded by BMO amid Gardasil, Keytruda concerns - Investing.com
Merck & Co Inc (MRK) DCF Valuation: Is The Stock Undervalued? - The Acquirer's Multiple
Merck & Co. Inc. stock outperforms competitors on strong trading day - MarketWatch
Merck & Co., Inc. (NYSE:MRK) Shares Up 0.5%What's Next? - MarketBeat
Merck's Investigational Two-Drug Regime For HIV Meets Primary Goal In Two Late-Stage Trials - Benzinga
Merck & Co (MRK) technical analysisMerck & Co (NYSE:MRK), Hansoh Pharmaceutical Gr (OTC:HNSPF) - Benzinga
Merck: encouraging phase III results in HIV - Marketscreener.com
Merck's HIV treatment meets main goal in two late-stage studies - Reuters
Merck Buys $50 Million of Personalis Stock - Marketscreener.com
Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna - Yahoo Finance
Merck shares reaffirm Market Perform rating on global in-licensing - Investing.com
Merck: Healthcare Pharma Giant: 3.2% Yield, 9.3% 5-Year Dividend Growth, Buy Time - Seeking Alpha
Merck Enters Obesity Space, Buys Rights to Hansoh's Oral GLP-1 Drug - Yahoo Finance
Merck’s RSV antibody could soon paddle into the rough waters of a crowded market - PharmaVoice
Merck's HIV-1 treatment meets efficacy in Phase 3 trials - Investing.com
Merck's HIV treatment meets main goal of two late-stage studies - Marketscreener.com
Merck stock slips after trial data for HIV drug (MRK:NYSE) - Seeking Alpha
Merck gets rights to Hansoh Pharma’s investigational diabetes drug - World Pharmaceutical Frontiers
Merck (MRK) Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir - StreetInsider.com
Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection - Business Wire
Why Is Merck & Co., Inc. (MRK) Among the Best Dividend Stocks to Invest In? - Yahoo Finance
Merck snags Chinese obesity drug in nearly $2 billion deal - Fortune
Merck (MRK) Stock Moves -1.72%: What You Should Know - Yahoo Finance
Deal Watch: Merck Decides Better Late Than Never In GLP-1 Deal With Hansoh - Citeline News & Insights
Merck & Co. Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Merck & Co., Inc. (NYSE:MRK) Stock Price Up 0.4%Still a Buy? - MarketBeat
Merck reaches weight-loss drug deal worth up to $2 billion with China-based Hansoh - Yahoo Finance
Merck & Co. taps Chinese biotech for entry into oral GLP-1 arena - FirstWord Pharma
Merck & Co buys in oral GLP-1 RA from China’s Hansoh - The Pharma Letter
Spotlight On: Merck enters the obesity game — four key takeaways - FirstWord Pharma
What's Going On With Viking Therapeutics Stock On Wednesday? - Yahoo Finance
Merck Acquires Potential Weight Loss Drug for $2 Billion - GuruFocus.com
Merck moves into obesity with deal for Hansoh’s GLP-1 pill - BioPharma Dive
Merck in global license agreement with Hansoh Pharma for weight-loss drug - ShareCast
Elon Musk, Netflix fined, Merck's GLP-1 deal: Market Minute - Yahoo Finance
Merck pens $2bn deal for obesity drug from China’s Hansoh - Proactive Investors USA
0.05%
0.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):